This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Nearly 70% of HCPs are now digital natives, with no interest in going back to pre-COVID sales engagement methods. To thrive in this environment, pharma needs to move from ad-hoc and reactionary digital transformation to long-term ‘digital excellence’, says Veeva’s Sebastien Noel. Market pressures. Achieving digital excellence.
Life sciences companies need to rethink their customer engagement paradigms in light of changing customer preferences. Pharmacompanies will need to continually rethink what works and not be afraid to experiment with solutions they’ve never tried before. As such, reps will need to be reskilled.
However, some of the pharmacompanies fared relatively well. Especially big Pharma players, such as Amgen, Pfizer, and BMS demonstrated high single-digit growth in sales during the recession. For example, 15 big pharmacompanies together laid off a total of over 71,000 employees during the great recession.
Gaurav Kapoor, co-founder and executive vice president of Indegene, tells pharmaphorum how pharma can take lessons from the entertainment industry and prepare for the Metaverse to enhance content engagement. Pharmacompanies’ customer communication methods require reimagining as technology progresses.
Aaron Gani, founder and CEO of BehaVR, and Krys Zaluski, director of businessdevelopment, digital health at Sumitomo Dainippon Pharma, discuss their groundbreaking partnership to develop and commercialise digital therapeutics (DTx) products. . They also understand how to do clinical trial design,” Gani states.
During the pandemic, numerous digital health companies flourished due to the necessity for virtual solutions, including Komodo Health. He oversees operations, including businessdevelopment, sales and marketing, and people. ” About the interviewee. Web Sun is co-founder and president at Komodo Health.
Another task for Pharma Consultants is Pharmacovigilance that is relatable to the collection, detection, assessment, monitoring, and prevention of adverse effects with biologicals, they also work in the area of resolving contamination issues. Pharma Consultancy Modus Operandi. Market Assessment & Operational Sales.
“We expect to see device and pharmacompanies start to think through the current decentralised models – increasing access to patients, increasing speed to recruit and complete studies, and empowering patients to have more ownership and access to clinical trials,” Sackman says. ” About the interviewees.
In the very beginning, it becomes a necessity for a Business Consultant to have appropriate knowledge about their client’s business. So discovering and learning about the company as a whole becomes essential.
SpringWorks Therapeutics — Badreddin Edris has been promoted from chief business officer to COO and Mary Smith, Mary Smith, currently senior vice president of Clinical Research and Development, has been promoted to chief development officer at SpringWorks. AB2 Bio – Swiss pharmacompany AB2 Bio Ltd.
Merck said the two drugs will “complement and strengthen” its cardiovascular pipeline – which has been somewhat eclipsed by its vaccines and oncology businesses in recent years. Sales of Reblozyl were $240 million in the first half of the year, as booked by BMS, with Acceleron claiming a $48 million share of the total.
Here, we will deep-dive into the top five fastest growing pharma and biotech companies in 2024, showcasing their innovative strategies and inspiring achievements. Pfizer (Overall Rank 268) Leading the list is one of the most renowned pharmacompanies in the world: Pfizer. Vertex is growing at a CAGR of 28.97
Big data analysis can be enormously powerful in providing insights for business strategy throughout the pharma value chain, including in the acceleration of drug discovery and development, optimization of manufacturing processes, management of supply chains and the creation of innovative sales and marketing strategies.
For example, global companies AstraZeneca and Johnson & Johnson partnered with vaccine manufacturers in India, a way to boost local production and use these companies’ networks to reach more countries. India and China have seen the emergence of strong, local pharmacompanies.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content